Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,213 across all filing types
Latest filing 2026-03-17 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Report Publication Announcement Classification · 100% confidence The document is a short announcement (1338 characters) from SSY Group Limited stating that a board meeting will be held on 27 March 2026 to approve the annual results for the year ended 31 December 2025. It does not contain the actual financial results, but rather announces the date of the meeting where those results will be approved and published. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2026-03-17 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from SSY Group Limited regarding the regulatory approval of a new product (Bumetanide). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate update regarding business development that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2026-03-16 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from SSY Group Limited regarding the approval of a new drug product (Fat-soluble Vitamin Injection (II)) by the National Medical Products Administration of China. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate update regarding business development that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2026-03-13 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement regarding a product development update (approval of a new medical material). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2026-03-13 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement regarding the approval of a new drug product (Calcium Levofolinate for Injection) by the National Medical Products Administration of China. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding business development that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2026-03-06 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from SSY Group Limited regarding the approval of a new drug product (Doxapram Hydrochloride Injection) by the National Medical Products Administration of China. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate update regarding business development that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2026-03-03 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.